| HIV-1 PHYLOG ENE TIC ANALYS IS
Phylogenetic analysis is a scientific process used to inspect small disparities in viral genes using computational techniques in order to determine the genetic distance between different strains. 4 The process begins with the generation of viral sequences, which are primarily derived from virions isolated from blood samples of HIV-infected persons. A detailed review of phylogenetic methods is documented elsewhere 5 and is beyond the scope of this review.
However, some applications of HIV phylogenetic analysis are summarised below.
Phylogenetic analysis is commonly used to identify the potential source of HIV-1 transmission events. 6 This allows scientists to rule out or confirm a possible specific partner or contact as the source of HIV infection. The analysis normally includes sequences of the suspected transmission case in addition to control datasets, which can be extracted from a genetic database and/or generated from other individuals infected with HIV in the same community. 7 If the two sequences are more closely related by genetic distance (the extent to which they have diverged from a common ancestor) to each other than they are to the comparison samples, and if the relationship was not by chance, it is assumed that the two individuals are in a linked transmission chain.
A classic example of the use of phylogenetic analysis to resolve a transmission case can be seen in the work of Goedhals and colleagues 8 who identified the source of a breastfed surrogate HIV-1 transmission event. In this case, researchers generated HIV-1 sequence data from the suspected transmission case (baby-case and his aunt and cousin) and analysed it together with control sequences, which had been collected in the local community. They then applied three methods for the construction of phylogenies (NJ, ML and Bayesian). These methods all showed that the sequences from the suspected transmission case were closely related based on statistical tests and estimates. The phylogenetic analysis supported interviews between public health officials and family members, which revealed that the aunt, who was HIV-1 positive, breastfed the baby-case when the baby's mother went to work.
Even though a large control dataset of sequences was used, the authors highlighted that phylogenetic analysis alone could not solve the case.
HIV phylogenetics can also be used in prevention trials. A good example was the HPTN-052 trial, which was designed to evaluate antiretroviral and other HIV interventions among HIV serodiscordant couples. In the trial, HIV-1 phylogenetic analysis was used to establish whether the HIV positive partner infected their HIVnegative partner. Results in this trial showed that 18.4% of new HIV infections in sero-discordant couples did not originate from their current primary partner. 9 Phylogenetic analysis was used with viral load clinical measurements and interviews to calculate the effectiveness of the trial. Another example of the use of HIV-1 phylogenetics was in the Partners in Prevention (PIP) trial, which estimated that 26.5% of new HIV infections were unlinked to the index HIV-positive partner. 10 Phylogenetic analysis can also be used for epidemiological purposes and is increasingly applied in studies that seek to understand population-based HIV transmission patterns and dynamics. For example, a large-scale phylogenetic study of HIV genetic sequences from men who have sex with men (MSM) in the Netherlands was used to determine the drivers of the underlying high-level transmission of HIV-1 in this population. 11 It was estimated that 71% of transmissions were from undiagnosed men and that 43% of the transmissions occurred in the first year of HIV-1 infection. The study also assessed the effectiveness of interventions to reduce HIV-1 transmission and found that increased annual testing coverage, pre-exposure ARV prophylaxis and immediate treatment were likely to avert 75% of new infections.
Routine HIV-1 sequence data has enabled public health practitioners to monitor HIV transmission hotspots in order to guide public health responses in near real time. Poon assessing and guiding the prevention of HIV transmission in the community. 13 Phylogenetic techniques are increasingly used to understand HIV-1 transmission in Africa. Findings from a phylogenetic study in Rakai, Uganda, showed that 44% of HIV infections were transmitted in stable household partnerships. Of those transmissions that occurred outside the household partnership, 62% were from individuals from another community. 14 Results from a recent community-wide phylogenetic study in South Africa showed that the majority of transmissions to young women (<25 years) were likely to be from men approximately 8.7 years older than them. 15 Lastly, HIV-1 phylogenetic analysis has also been widely used in forensic work. This has predominantly been applied in countries where HIV transmission is criminalized. 16 As Abecasis and colleagues 17 argue, the use of phylogenetics as evidence in court should be seen in the context of hypothesis testing. A normal court null hypothesis is that the defendant infected the victim. In such cases, phylogenetic analysis and expert testimony are used to provide evidence that supports or refutes the null hypothesis. While phylogenetics can sometimes prove innocence, it is not possible to use phylogenetics alone to make a guilty verdict 18 . Furthermore, phylogenetic analysis alone cannot provide definitive proof of the route, direction and timing of HIV transmission between two people. There may be other possible reasons why the two individuals have similar viruses. For example, a third person may exist, who is the original source of the transmission event, but who was not sampled. 19 Phylogenetic analysis is most informative when HIV sequences are linked to clinical, demographic and behavioural data of the sampled individuals. Sources of this data could be medical records and surveys, which contain demographic, clinical and sexual behaviour information. The source of the genetic material used in HIV-1 phylogenetic analysis is the virus itself, not human genes.
For this reason, the ethical issues traditionally linked to human genetic research, such as privacy and confidentiality, fears of stigma and discrimination, may, at first glance, appear to be of little concern. A closer examination, however, reveals distinct ethical considerations.
| AN E THI C AL FR AME WORK FOR THE RE VIE W OF HIV PHYLOG ENE TIC S RE S E ARCH: THE EMAN UEL , WENDLER AND G R ADY FR AME WORK
In order to systematically review and organise the literature, we used a frequently cited 20 ethics framework developed by Emanuel, Wendler and Grady. 21 The framework is referred to as the Emanuel Framework (EF) throughout this review. We chose the EF primarily on merit. The EF was developed from content analysis of several major international normative ethics research guidelines. Although initially developed for clinical research in developed countries, the EF has since been adapted for use in developing countries 22 and for the review of other types of research, notably, social science 23 and health systems research. 24 Additional uses of the EF are documented elsewhere. 25 Because we assumed that the EF could usefully accommodate most of the ethical issues in HIV phylogenetic research, the EF is outlined in detail below, followed by an identification of the key ethical issues in HIV phylogenetic research using the same framework. A conceptual issue that may create problems with community engagement efforts for phylogenetic research is that communities are often not stable, static entities with clearly defined boundaries. 13 Rather, they are fluid and may consist of sub-communities whose members may not share similar research needs and priorities. It may, therefore, be difficult to identify legitimate community members and stakeholders to help plan and conduct the study and disseminate the results. Even more challenging could be the identification of representatives of relevant communities who have the best interests of the target community at heart.
| Community participation
Evaluating the success and adequacy of community engagement may also be difficult, particularly in the absence of clearly defined matrices for its assessment. 26 Similarly, considering the number of players in the engagement process in a given community, there should be consensus on who legitimises the community engagement process. Such issues are not always straightforward as different stakeholders and levels of authority in a community might possess conflicting views.
HIV phylogenetic research can have a positive (for example, better prevention and treatment programmes) or negative (for example, stigma associated with HIV transmission for sub-groups identified as high transmitters) impact on communities. For this reason and due to its complexity, investigators need to invest heavily in community engagement efforts 27 in order to ensure that research messages are appropriately packaged for target audiences. Inappropriate messaging could undermine the validity of informed consent, exposing communities and research participants to risk of exploitation.
| Social value
Research should address socially valuable questions in order to justify involving human participants. 28 An example of a valuable question is one that generates new knowledge or understanding on human health or illness. It is therefore critical that in developing research projects, researchers should identify the study beneficiaries and outline the benefits that will accrue to them. Benefits can be classified as direct or indirect and can occur immediately or at a later date. 29 It is also important to develop mechanisms that enhance the value of research and to consider the potential impact of the research on the existing health-care infrastructure and social system. 30 HIV phylogenetic research can potentially benefit both HIV positive and negative individuals, communities affected with HIV and AIDS, health systems and society at large. Comparatively, its contribution could be more pronounced in sub-Saharan Africa where the HIV burden is greatest. When phylogenetic analysis of HIV sequences is used in conjunction with detailed epidemiological, clinical, demographic and behavioural data, it generates rich information on HIV transmission dynamics at community, regional and country levels. 31 Apart from journal publications, conference presentations and policy briefs, community feedback meetings could also be organised to ensure that results reach grassroots levels and that the views of the community are taken into consideration. Another approach that may enhance social value is to integrate phylogenetic research into longterm health strategies and/or public health programmes.
Another important aspect of social value is to assess the impact of the research on health-seeking behaviour. For example, HIV phylogenetic research can be seen as a threat to individual privacy as HIV phylogenies can potentially identify individuals that are linked to population groups that are stigmatised or penalized, such as MSM or sex workers.
These individuals may avoid positive health-seeking behaviours that could benefit themselves and the population out of fear of stigma or prosecution. For example, they may refrain from HIV diagnosis and drug resistance testing and this may lead to new infections and continued transmission of HIV drug resistant strains. 33 Similarly, individuals may avoid participating in studies that use HIV genetic data. The social value of HIV phylogenetic research is further discussed in this review under the ethical principle of Favourable risk-benefit ratio.
| Scientific validity
The study design should be rigorous enough to ensure that valid, reliable, interpretable and in some cases generalizable data is 26 generated. Scientific rigor and integrity are key elements of ethical research. Poor quality science is normally produced by the use of unreliable and/or invalid research methods. It also constitutes unethical conduct because if results from such studies are not trustworthy, resources are wasted and research participants are exposed to potential risk of harm and inconvenience for no apparent benefit. 34 To ensure scientific validity, researchers and their associates should be competent to implement the proposed study design. In order to maximize scientific validity, the researchers should ensure that they have all necessary resources, that the community accepts the protocol and that a competent and independent research ethics committee (REC/IRB) reviews and approves the protocol.
HIV phylogenetics currently has methodological shortcomings, which require expert consideration to avoid or minimise erroneous 
| Phylogenetics and direction of transmission
One of the key limitations of HIV phylogenetic analysis is its inability to provide definitive proof of direction of HIV transmission between two people on its own. This lack of certainty and precision has raised concerns about the reliability of phylogenetic analysis in reconstructing the HIV transmission history between two or more individuals in a phylogenetic cluster. 35 In HIV forensics, these problems potentially result in miscarriages of justice through erroneous convictions or acquittals, hence the need to interpret results with extreme caution. 36 In the absence of specific evidence on the source of transmission, those considered undesirable in society may face prosecution. 37 Apart from criminal prosecution, phylogenetics analysis could also have serious implications for the course of justice in civil cases.
| Effects of co-infection and super infection
The difficulty in identifying the precise source of HIV is compounded by the fact that HIV infection can be caused by more than one strain that is constantly mutating, recombining and evolving into different strains, even within the same individual. 38 In addition, over time, individuals may be infected with different HIV strains that have genetically distinctive characteristics. 39 Certain viral sequences, especially those generated from direct Sanger sequencing techniques, may not fully represent the viral diversity within an individual. 40 This may bias the analysis and have serious consequences.
| Lack of standard phylogenetic cut-offs for the identification of transmission clusters
An HIV cluster is a group of sequences that are more similar to each other than to other sequences in the same dataset, based on a predefined criterion or algorithm. However, there is no gold standard measure for clustering, hence the definition of a cluster remains largely subjective. 41 Furthermore, although several genetic clustering methods and related computer software are widely available, most of these methods have neither been validated on already known clusters nor evaluated using the same dataset. The interpretation of HIV genetic clusters may, therefore, be ambiguous and biased, which could lead to misplaced priorities for HIV interventions.
As one author observed, due to the methodological issues highlighted, "… the research community needs to have greater skepticism about clustering methods and, ultimately, to reach a consensus on best practices for generating and interpreting clusters.". 42 Nonetheless, the application of clustering methods is common, with opportunities for improvement. A review of the impact and shortcomings of clustering methods is documented elsewhere 43 and is beyond the scope of this paper.
| Fair participant selection
The scientific objectives of research should guide the choice of participants and determine the inclusion criteria and appropriate recruitment strategies. It is unethical to use privilege, convenience and/or vulnerability as criteria for selecting participants. Exclusion of certain population sub-groups or communities in a research study without appropriate scientific justification is also considered unethical. Those who are selected to participate in the study should also be informed of the research results and receive any benefit that comes from them. In the next paragraphs, we will discuss the two remaining 
| Sampling coverage

| Use of appropriate control samples
To enhance the validity and reliability of phylogenetic analysis, appropriate control samples must be used. These controls should come from the same viral subtype and geographic region and should ideally be collected and sequenced at the same time. Strict laboratory protocols and standards should also be followed. 45 Such precautions are especially important for forensic cases or complex cases of HIV transmission. For example, in the infamous Lafayette case, a gastroenterologist was convicted of attempted second-degree murder for injecting his former girlfriend with HIV-1. In their evidence, the researchers needed to generate control datasets for HIV-1 positive individuals from the same area and use two distinct laboratories with strict control protocols. 46 Another example already mentioned, was the use of a large control dataset of thousands of sequences to solve the HIV-1 transmission surrogate case in South Africa. 47 In the study of the MSM epidemic in the Netherlands, large datasets of HIV-1 control sequences from Europe were needed to identify transmission clusters. 48
| Favourable risk-benefit ratio
A favourable risk-benefit ratio is realised when research benefits and burdens are fairly distributed. 49 risks, it is critical to consider the probability of harm occurring, as well as its severity.
The benefits of data sharing to advance scientific progress and public health are widely acknowledged. 51 Sharing of sequence datasets can help formulate and address new research questions, inform the design and implementation of future epidemiological studies and provide a unique opportunity for meta-analyses of available data, which can be used to track and predict future epidemics. 52 Access to datasets enables other researchers to critically evaluate published results, which might foster greater integrity among researchers. In addition, this minimises the costs of generating additional data.
However, there is a tension between the public health benefits of data sharing and the risk to privacy for individuals whose data is used in HIV genetic research.
In spite of the increased accessibility of genomic sequence data there are no adequate laws, regulations and guidelines that protect individual privacy. 53 For example, a global privacy governance framework for genomic databases, and by extension genomic research, is non-existent. 54 Furthermore, where available, national guidelines on privacy are often inadequate, fragmented, diverse and complicated. This was illustrated by results of an analysis of laws from twenty developed and developing countries. 55 Although the reviewed legislation and frameworks were conducted with biobanks in mind, similar concerns may also arise in phylogenetic research because of its reliance on genomic databases. The existing ethical and legal framework could therefore hinder collaborative research across national borders. Another challenge is the absence of a clear definition of what the true benefit or actual risk is in the context of HIV molecular epidemiology research. 56 In their seminal host genetics study, Gymrek and colleagues demonstrated that individuals who participated in a genomic study could be identified using free publicly available information even though their genetic and personal information was stored in databases in de-identified form. 57 In the consent documents for the study, the risk of re-identification was only mentioned as a distant possibility. This implied that the researchers and possibly the research participants did not fully understand the risks to privacy at the onset of the genetic study. Other studies have also raised similar privacy concerns. 58 The privacy threats mentioned above occurred in host genetic studies. However, similar violations could occur in HIV genetic studies because the viral sequence is traceable to its human host.
For example, a person can have access to his own HIV drug resistance genotype and search public databases, allowing the identification of closely related sequences. Additionally, advances in genomic techniques like NGS and their increased availability enable scientists to draw more accurate conclusions about HIV transmission between individuals. 59 Such advances could provide robust information that may lead to loss of privacy. 60 The loss of privacy and the inadvertent disclosure of HIV status for people who might have transmitted the virus in a transmission network are primary concerns underlying the sharing of HIV sequence data and transmission network analysis. 65 On the one hand, the uniqueness of the virus enables useful detailed molecular epidemiological analysis for clinical management (for example drug resistance testing for HIV treatment), public health interventions and prevention efforts. On the other hand, however, analysis of HIV sequence data can potentially reveal identifying information. 66 This is complex, because researchers have an obligation to report their findings truthfully, but also have parallel obligations to prevent and minimise foreseeable harm to participants and the community.
It is hard to quantify and preserve privacy in the context of HIV molecular epidemiology and its application in public health and management of patients. This is because of the absence of appropriate methods for assessing privacy. 67 Traditionally, de-identification of genetic data, which is achieved by the removal of specific identifiers, was a useful approach for the protection of privacy in research settings. However, de-identification has its own problems. Essentially, de-identification requires one to identify all the risks associated with re-identification of individuals and to establish what constitutes a threshold for safety. 68 This presents both conceptual and measurement challenges since quantifying the privacy properties of data is difficult in the context of genomic data. 69 Additionally, deidentification cannot guarantee the protection of privacy due to the ubiquitous nature of data and the increasing ability of scientists to triangulate data from different sources. De-identification also minimises the utility of the data, 70 particularly in molecular epidemiological studies where certain variables are required to make informed conclusions. For example, without linking HIV sequences to selected socio-demographic variables, it is not possible to generate models that predict transmission patterns or to evaluate the impact of interventions.
| Independent ethics review
Prior to data collection, study protocols should be subjected to an independent, properly constituted and competent REC/IRB to give a dispassionate view of the protocol. Apart from assessing whether ethical and regulatory requirements are fulfilled, independent ethics review is also meant to check for any biases and conflicts that the researcher(s) might have. Ultimately, the review provides assurance to the public that individuals and groups will not be exploited. 71 The overall objective of ethics review is, therefore, to maximise protection of research participants while enhancing the quality of research. Scientific validity will also be scrutinised. The review will include appropriateness of the methods, balance between risk of harms and potential benefits and whether there are alternative and less risky methods of answering the same research question. Furthermore, the informed consent process and fair selection of study participants and how they are treated will also be examined. 
| Informed consent
The requirement for informed consent is based on the principle of respect for persons. It ensures that research participants are given a chance to make decisions on whether they want to join a study, continue participation and whether their decision is in line with their aspirations, values, beliefs and interests. Informed consent has five main elements: information disclosure, competence, understanding, voluntariness and formalization of the agreement. 75 In practical terms, informed consent requires researchers to provide prospective research participants with clear, unbiased, detailed and factual information about the study. The information disclosure ordinarily covers information on study methods, potential risks and benefits as well as assertions that participation is at the sole discretion of the research participant and that they can refuse to join or may withdraw from the study at any time without suffering negative consequences. 76 Information about the study risks, procedures and benefits must be disclosed to the prospective participants in a way that facilitates comprehension.
A key concern in health research globally and with particular reference to Africa is the quality of informed consent. 77 Empirical research has shown that participants may not receive adequate information about the study or may fail to understand research procedures and key concepts, 78 particularly where complex studies are conducted in resource limited settings. By their nature and design, HIV phylogenetic studies are complex, as described above. When conducted in resource-limited settings where many prospective research participants are illiterate, research-naïve and have limited access to healthcare services, such studies may be poorly understood and thus lead to invalid consent (or refusals), thereby undermining the ethical integrity of the study.
A major concern in HIV phylogenetic research is the amount of information that prospective research participants receive and how such information is best presented to guarantee valid consent. 79 On the one hand, detailed and inappropriately packaged information might scare prospective participants, while on the other; too little information might undermine valid consent. A related concern is that researchers have to explain complex technical terms to prospective participants. The mother tongue of some prospective participants may not have equivalent words for these concepts so they may be difficult to understand. Scientific terms like DNA, genes and se- 
| Ongoing respect for participants
Ethical research requires that the rights and welfare of research participants be respected during and after the study. Research participants cannot be separated from the communities in which they live. One cannot respect an individual and at the same time disregard their communities.
Phylogenetic research is complex as it may utilise existing databases from routine medical care, which may contain confidential social, clinical and demographic information, which could lead to the identification of individuals or social groups if not properly managed.
Access and governance of such databases can pose systemic harms to individuals and communities through HIV disclosure, genetic or HIV related discrimination, stigmatisation, lawsuits and social disharmony, among others. In the absence of clear and evidence-based guidance on access to such databases and on phylogenetic research in particular, these problems may be worsened.
HIV has been and remains stigmatised since the discovery of the virus three decades ago. Stigma and discrimination are harmful social phenomena, which affect both individuals and social groups.
Those who suffer most are the already or historically marginalised, for example, women, black people, commercial sex workers, injecting drug users, sexual minorities and people from specific geographic locations. Incidents of HIV related stigma and discrimination are well documented. 86 Stigma and discrimination can lead to fear of HIV testing and disclosure. This fuels transmission since the infected person cannot access treatment without being tested. 87 In countries where HIV transmission is criminalized, knowledge of HIV status is avoided to protect individuals from prosecution. This is because if they know their HIV status, the law requires HIV positive individuals to act responsibly in order to avoid infecting others. 88 Failure to do so can lead to prosecution for intentionally transmitting HIV. In an effort to avoid prosecution, individuals may shy away from tests that benefit their health and the community, for example, HIV and drug resistance testing. 89 Stigma and discrimination are real risks in HIV transmission network analysis, as discussed above, although the problem is not unique to HIV phylogenetics.
| CON CLUS ION
HIV phylogenetics is a relatively new field and limited conceptual and empirical work has been conducted to explore the ethical issues it raises. To review the body of knowledge in this field, we applied the Emanuel, Wendler and Grady Framework (EF). Its principles mimic the sequence of a research project, starting with the design and ending in the communication of the results to the participants of the study and the community at large. To the best of our knowledge, this is the first review to use the EF to analyse research in HIV phylogenetics. While the EF was instrumental in guiding the structure of this review, it was evident that some themes could fall under more than one ethical principle. For example, the discussion on sampling, which was covered under 'Fair participant selection', could equally fall under 'Scientific validity'. The same applies to issues of 'Community engagement' and 'Informed consent', which are interrelated. It is possible that other ethical considerations associated with HIV phylogenetics may not fit within the EF. 84 Mello MM, Wolf LE. The Havasupai Indian Tribe case--Lessons for Research Involving
